- Christine M. Walko, Pharm.D., discusses how advancements in technology have improved the quality, cost and turnaround time for assessing genetic mutations in tumor tissue, and how this has helped to translate precision medicine into standard clinical practice.
Divergent Paths for Tagrisso (Osimertinib) and Rociletinib for EGFR T790M Mutation-Positive NSCLC and Acquired Resistance: What Happened, and Where Are We Now?
Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.
Drs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers progress.
Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In this video he details what should go into the decision to modify treatment for those patients.
Acquired resistance in EGFR patients is often driven by the T790M mutation. T790M-positive tumors respond differently to treatments than T790M-negative tumors. Dr. Greg Riely details how each status can predict patients' responses to current treatments.
Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active in acquired resistance and consider whether there are significant differences between them.
Are There Clinically Significant Differences Among the First and Second Generation EGFR TKIs (Iressa, Tarceva, Gilotrif)?
Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).
Should Third Generation EGFR Inhibitors Be Used Before First Generation EGFR TKIs or After Progression?
Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.
Clinical Trial Spotlight: Options for EGFR Mutation-Positive Patients with T790M Mutation-Negative Acquired Resistance
Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation, focusing on a clinical trial with the novel hypoxia-induced pan-HER inhibitor TH4000.